LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
235 Views
Biopharma Week in Review - July 15, 2024
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
243 Views
SPAC Talk: Which IBC Deals Could Be Under Threat?
KEY HIGHLIGHTS The haves.... The momentum of new deals continues to flow strongly. Ten new IBC deals have been announced so far in October, with a...
680 Views
Longeveron Inc. - Investment Thesis, Key Drivers, Financial & Price Forecasts, DCF Valuation 9/21
Longeveron Inc. (“Longeveron”) is a leading clinical stage biotechnology company developing cell therapies for chronic aging-related diseases and...
27 Views